Enlivex Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ENLV | VRAX | AIM | CELZ | NOX.AX | XRTX | |
|---|---|---|---|---|---|---|
| Market cap | 2.13M | 1.61M | 6.42M | 4.95M | 10.75M | 1.80M |
| P/E (TTM) | 0.0 | — | — | — | — | — |
| Forward P/E | -1.8 | -0.2 | -0.4 | -0.7 | — | 1.2 |
| Price/book | 0.0 | 0.1 | 0.6 | 0.5 | -2.9 | 0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −99.39% | −90.40% | −90.78% | −75.95% | −64.00% | −65.92% |
| Today | −4.79% | +13.21% | +0.19% | −3.21% | −2.78% | −1.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All ENLV news ›Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
Nasdaq Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal Oct 27, 2026 8:00am EDT Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Learn more about this Enlivex Investor Relations update > Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ i
Enlivex Therapeutics trading halted, news pending
19:50 EDT Enlivex Therapeutics (ENLV) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving... Enlivex Therapeutics trading halted, news pending 19:50 EDT Enlivex Therapeutics (ENLV)…
Enlivex faces Nasdaq delisting risk, plans appeal
Enlivex faces Nasdaq delisting after missing the $1 bid rule. - Enlivex (ENLV) received a Nasdaq delisting notice dated October 26, 2026, for failing to meet the $1 minimum bid price requirement for 30 consecutive business days. - Due to a…
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ('Enlivex' or the 'Company'), a quality longevity company pow... Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens…
Enlivex Therapeutics target adjusted to $80 from $20 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on Enlivex Therapeutics (ENLV) to $80 from $20 and keeps a Buy rating on the shares. The firm c... Enlivex Therapeutics target adjusted to $80 from $20 at H.C. Wainwright H.C. Wainwright…
Enlivex Therapeutics Stock Set to Reverse Split on Tuesday, October 27th (NASDAQ:ENLV)
Posted by Sarita Garza on Oct 24th, 2026 Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Free Report)’s stock is going to reverse split on the morning of Tuesday, October 27th. The 1-16 reverse split was recently announced. The number of shares…
Enlivex announces 1-for-16 reverse stock split
Enlivex will enact a 1-for-16 reverse stock split on October 27, 2026. Enlivex (ENLV) will implement a 1-for-16 reverse stock split effective October 27, 2026, with shares trading on a split-adjusted basis on Nasdaq. The company’s issued…
More from 1 other outlet
Enlivex Therapeutics to reduce workforce by 60%
Enlivex announced a cost reduction plan, effective immediately, designed to substantially reduce the company’s cash burn and focus its resources... Enlivex Therapeutics to reduce workforce by 60% Enlivex announced a cost reduction plan,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com7
- seekingalpha.com3
- investors.enlivex.com1
- nasdaq.com1
- quiverquant.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.